Related Experiment Video

Updated: Aug 18, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

[NOD2/CARD15 gene polymorphisms and susceptibility to Crohn's disease in Chinese Han population]

Min Gao1, Qian Cao, Ling-he Luo

  • 1GI Division of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.

Zhonghua Nei Ke Za Zhi
|April 21, 2005
PubMed

Insights

The NOD2/CARD15 gene variants associated with Crohn's disease (CD) in Caucasians were not found in the Chinese Han population. This study indicates no link between these common NOD2/CARD15 polymorphisms and CD susceptibility in this ethnic group.

Area of Science:

  • Genetics
  • Gastroenterology
  • Immunology

Context:

  • Crohn's disease (CD) is a chronic inflammatory bowel disease with a complex genetic basis.
  • NOD2/CARD15 gene polymorphisms are established risk factors for CD in Caucasian populations.
  • Previous research has shown ethnic variations in the association between NOD2/CARD15 and CD.

Purpose:

  • To investigate the association between common NOD2/CARD15 gene polymorphisms and susceptibility to Crohn's disease in the Chinese Han population.
  • To determine if the NOD2/CARD15 gene plays a role in CD pathogenesis in this specific ethnic group.

Summary:

  • Genotyping for three common NOD2/CARD15 polymorphisms (Arg702Trp, Gly908Arg, Leu1007fsinsC) was performed on 32 CD patients, 110 ulcerative colitis patients, and 292 healthy controls from Zhejiang, China.
  • No heterozygous or homozygous single nucleotide polymorphism (SNP) variants of NOD2/CARD15 were detected in CD patients, ulcerative colitis patients, or healthy controls.
  • The study found no association between the investigated common NOD2/CARD15 variants and Crohn's disease in the Chinese Han population.

Impact:

  • This research highlights the ethnic-specific genetic factors contributing to Crohn's disease.
  • Findings suggest that genetic screening for these specific NOD2/CARD15 variants may not be beneficial for diagnosing CD in the Chinese Han population.
  • Contributes to a better understanding of the genetic architecture of inflammatory bowel disease across diverse ethnicities.
Abstract

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...